To this end, NSCLC cell treatment with low doses of silibinin (i.e., 3.75–12.5 μM) in combination with TSA and 5-AZA, restored the expression of E-cadherin and downregulated the expression of ZEB1 (its transcriptional repressor) [70]. This evidence concerns the gene CDH1 and non-small cell lung carcinoma.